Long-term_therapy_of_HIV-associated_Kaposi's_sarcoma_with_recombinant_interferon_alpha-2a._Five_young_male_patients_with_HIV-associated_Kaposi's_sarcoma_(KS)_were_treated_with_recombinant_interferon_alpha_2a_(rIFN-alpha-2a)_over_a_period_of_2-2.5_years._An_IFN_dose_of_18_x_10(6)_IU_was_given_subcutaneously_every_day_during_the_first_3_months_of_treatment_and_then_on_alternate_days._Additional_treatment_with_radiotherapy_and_laser_therapy_was_given_and,_in_some_cases,_isolated_skin_nodules_were_excised._Within_7_months_of_initiation_of_therapy_one_patient_had_a_complete_remission_of_his_tumours,_however,_tumour_progression_recurred_after_the_patient_discontinued_treatment._In_another_patient_the_tumour_cleared_within_9_months_of_rIFN_therapy,_and_after_52_months_he_is_still_free_of_KS._The_condition_of_a_third_patient_tended_to_become_stabilized_during_the_first_6_months_of_therapy,_but_after_60_months_there_has_been_a_slow_progression._The_fourth_and_fifth_patients_died_25_and_28_months,_respectively,_after_the_histological_diagnosis_of_KS_and_the_initiation_of_treatment._While_on_therapy_with_rIFN-alpha-2a,_no_life-threatening_opportunistic_infections_occurred._The_side-effects_were_mostly_well_tolerated,_and_no_severe_changes_in_haematological_parameters_were_caused_by_the_therapy.